CLAIMS

1. A composition comprising a colloidal particle comprising (i) about 0.5 to 20 mole percent of a first amphipathic lipid derivatized with a biocompatible hydrophilic polymer and (ii) a second amphipathic lipid for use in the treatment of haemophilia A, in which the composition is formulated as a buffered aqueous formulation and in which the composition does not contain any pharmaceutically active agent or exogenous protein.

2. A composition for use according to Claim 1, in which the colloidal particles are substantially neutral and the polymer carries substantially no net charge.

3. A composition for use according to Claim 1 or 2, in which the colloidal particle has a mean particle diameter of between about 0.03 to about 0.4 microns (μm), optionally in which the colloidal particle has a mean particle diameter of approximately 0.1 microns (μm).

4. A composition for use according to Claim 1, 2 or 3, in which the first amphipathic lipid is a phospholipid from natural or synthetic sources, optionally in which the first amphipathic lipid is a phosphatidylethanolamine (PE).

5. A composition for use according to Claim 1, 2 or 3, in which the first amphipathic lipid is a carbamate-linked uncharged lipopolymer, optionally in which the first amphipathic lipid is aminopropanediol distearoyl (DS).

6. A composition for use according to any preceding claim, in which the second amphipathic lipid is obtained from either natural or synthetic sources, optionally in which the second amphipathic lipid is a phosphatidylcholine (PC).

7. A composition for use according to Claim 6, in which the colloidal particle comprises palmitoyl- oleoyl phosphatidyl choline (POPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine (DSPE) in a ratio (POPC:DSPE) of from 85 to 99:15 to 1, optionally in which the ratio of POPC:DSPE is from 90 to 99:10 to 1, optionally in which the ratio of POPC:DSPE is 97:3.

8. A composition for use according to any preceding claim, in which cholesterol is supplemented to the composition.

9. A composition for use according to any preceding claim, in which the biocompatible hydrophilic polymer is selected from the group consisting of polyalkylethers, polylactic acids

and polyglycolic acids, optionally in which the biocompatible hydrophilic polymer is polyethylene glycol.

10. A composition for use according to Claim 9, in which the polyethylene glycol has a molecular weight of between about 500 to about 5000 Daltons, optionally in which the polyethylene glycol has a molecular weight of approximately 2000 Daltons.

11. A composition for use according to Claim 9 or 10, in which the derivatized amphipathic lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)].

12. A composition for use according to Claim 9, 10 or 11, in which the derivatized amphipathic lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine-N-[poly-(ethyleneglycol)-2000] (DSPE-PEG 2000).

13. A composition for use according to any preceding claim, in which the composition is formulated for intravenous or subcutaneous administration.

14. A composition for use according to any preceding claim, in which the composition further comprise a non-ionic surfactant.

15. A composition for use according to Claim 14, in which the non-ionic surfactant is selected from the group consisting of polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxyethylene laurylethers.

16. A composition for use according to Claim 14 or 15, in which the composition is formulated for topical, intravenous or subcutaneous administration.

17. A kit of parts comprising a composition according to any preceding claim and an administration vehicle including injectable solutions for administration for use in the treatment of haemophilia A.

18. A dosage form of a composition according to any preceding claim for use in the treatment of haemophilia A.